Tinnitus Research Digest: Mental Health Burden, Integrated Care, and Medication-Linked Cases

This cross-sectional study enrolled 100 adults with chronic subjective tinnitus (at least six months’ duration) attending a tertiary otolaryngology outpatient clinic. Participants completed the Tinnitus Handicap Inventory (THI), Beck Depression Inventory-II (BDI-II), and Beck Anxiety Inventory (BAI). The sample is not population-representative — these are patients already seeking specialist care, which likely skews severity upward.

Mean THI scores indicated moderate-to-severe tinnitus distress. Clinically relevant depressive symptoms were identified in 28 out of 100 participants, and anxiety symptoms in 31 out of 100. Tinnitus severity showed a moderate positive association with both depression (r = 0.50) and anxiety (r = 0.48). After adjusting for age, sex, and hearing status, tinnitus severity remained independently associated with both outcomes. Participants with severe tinnitus (THI score at or above 58) had approximately three times the odds of moderate-to-severe depression compared with those with lower THI scores (OR 3.10, 95% CI 1.52 to 6.30).

Because this is a cross-sectional design, it cannot establish whether tinnitus causes psychological distress or whether pre-existing anxiety and depression amplify tinnitus perception — most likely the relationship runs in both directions. Replication in larger, more diverse populations and longitudinal designs are needed to clarify causality.

This paper describes the Sensation-Emotion-Cognition (SEC) model, an audiological management framework developed by Danesh et al. that addresses three dimensions of tinnitus experience: sensory, emotional, and cognitive. The SEC protocol combines sound therapy, counseling and relaxation training, and cognitive behavioral therapy (CBT), delivered through unguided internet CBT, clinician-guided internet CBT, or six therapist-led sessions. The paper integrates findings from a retrospective cohort and a prospective expansion study.

The prospective component included 16 participants who completed the study. Pre-post comparisons showed increases in management confidence (mean score rising from 30.38 to 60.19) and reductions in tinnitus-related distress. However, the study used a single-group pre-post design with no control group, which means improvements cannot be attributed specifically to the SEC protocol rather than to the passage of time, attention from clinicians, or other factors. The study also experienced participant attrition, and only 16 completers are reported, making statistical conclusions unreliable.

The authors themselves flag these limitations and describe the findings as exploratory. Larger randomised controlled trials with active control arms are needed before any conclusions about the effectiveness of the SEC model can be drawn.

This case report describes a 30-year-old woman who developed unilateral pulsatile tinnitus and blurred vision shortly after starting isotretinoin (a retinoid medication commonly prescribed for acne). She was diagnosed with drug-induced intracranial hypertension (DIIH). Despite stopping isotretinoin, escalating the medication acetazolamide, and undergoing multiple therapeutic lumbar punctures, her pulsatile tinnitus persisted at one year follow-up. Neuroimaging identified a high-riding jugular bulb with diverticulum and possible sigmoid sinus dehiscence, anatomical findings that may have contributed to symptom persistence after the medication-related pressure resolved.

This is a single case report (n=1), which means it describes an individual experience rather than establishing frequency of this complication or outcomes across patients. DIIH caused by isotretinoin is a recognised but uncommon adverse effect; the persistence of pulsatile tinnitus beyond drug cessation in this case appears linked to coexisting anatomical factors specific to this patient.

What this case adds is a reminder that not all cases of DIIH resolve cleanly after stopping the causative drug, particularly where underlying vascular or structural variants are present. Broader study in patients with DIIH-related pulsatile tinnitus would be needed to understand how often persistence occurs and what predicts it.

This educational case report presents a 57-year-old man with recurrent vertigo, progressively worsening right-sided sensorineural hearing loss, tinnitus, and a documented severe vitamin D deficiency. The report was produced primarily to support medical students’ understanding of Ménière’s disease and was published in Cureus, a peer-reviewed journal that frequently publishes educational and case-based content.

The case underwent comprehensive workup including pure-tone audiometry, vestibular testing, and imaging. Management included lifestyle and dietary modifications, pharmacological therapy, vestibular rehabilitation, vitamin D supplementation, and hearing aid fitting. The authors report improved vertigo control, balance, and quality of life, though no standardised outcome measures or pre-post scores are provided, which limits interpretation.

The report discusses the pathophysiology of Ménière’s disease, noting that endolymphatic hydrops remains the hallmark histopathological finding but that its underlying cause is not fully understood and likely varies between patients. Vitamin D deficiency is described as an emerging modifiable factor, though the report does not present evidence that supplementation specifically altered the disease course in this case.

As a single educational case report, this does not establish new treatment options or diagnostic criteria. It reflects existing clinical practice rather than advancing it.

Based on the available information, this is a 1995 case report on the use of alprazolam, a benzodiazepine, for tinnitus symptom management. No abstract is available, so study design, sample size, and outcome measures cannot be confirmed. The entry is listed under authors Linh Hiivnh and S. Fields.

Alprazolam and other benzodiazepines have been studied for tinnitus for several decades. Some evidence from this era suggested modest reductions in perceived tinnitus loudness, but these drugs carry well-established risks including tolerance, dependence, and withdrawal effects. They are not a standard recommended treatment for chronic tinnitus in current clinical guidelines.

At 30 years old, this publication does not represent new information. No conclusions about current clinical practice should be drawn from a single historical case report without an available abstract. The mechanisms and evidence base for benzodiazepines in tinnitus have been examined in subsequent, better-controlled work, none of which has produced strong enough evidence for routine clinical adoption.